ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RLMD Relmada Therapeutics Inc

3.68
-0.04 (-1.08%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Relmada Therapeutics Inc NASDAQ:RLMD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.04 -1.08% 3.68 3.56 3.95 3.93 3.63 3.80 92,915 05:00:06

Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Sto...

10/12/2019 1:00pm

GlobeNewswire Inc.


Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Relmada Therapeutics Charts.

Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing depression and central nervous system disease therapies, in the successful completion of an underwritten public offering of three million shares of Relmada common stock at a price of $30.00 per share.

The underwriters exercised their over-allotment option for an additional 450,000 shares, bringing gross proceeds to $115 million before the deduction of underwriting discounts, commissions, and other estimated offering expenses. Jefferies, SVB Leerink, and Guggenheim Securities are joint book running managers for the offering.

Relmada intends to use the net proceeds to fund research and development for clinical stage programs related to its lead product candidate, REL-1017 (d-methadone), an oral agent for depression which recently produced favorable results in clinical trials.

Sichenzia Ross Ference LLP also represented Relmada in the listing of its Common Stock on the Nasdaq Capital Market, which commenced trading on October 10, 2019. The firm joined Relmada and its executive leadership at its Nasdaq Bell Ringing Ceremony on October 17.

The Sichenzia Ross Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe, Barrett DiPaolo, Thomas Rose and Associate Grant Levine.

About Sichenzia Ross Ference LLP Sichenzia Ross Ference LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. Our attorneys specialize in advising clients in private placements, initial (IPOs) and secondary public offerings, mergers and acquisitions (M&A), preparation of SEC filings and listing to major stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. The firm also complements its core practice areas with an established commercial real estate and trusts and estates practice. Visit www.SRF.law to learn more, and follow the Firm on TwitterLinkedIn and Facebook.

For Media Inquiries: eric@fischtankpr.com 646 699 1148

1 Year Relmada Therapeutics Chart

1 Year Relmada Therapeutics Chart

1 Month Relmada Therapeutics Chart

1 Month Relmada Therapeutics Chart

Your Recent History

Delayed Upgrade Clock